Genelux (GNLX) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Genelux (GNLX) over the past year, losing 13.1% versus a loss of 54.9%. Genelux is the larger company by market cap ($115.8 million vs $112.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | UNCY |
|---|---|---|
| Share price | $2.56 | $4.11 |
| Market cap | $115.83M | $112.59M |
| 1-day change | +2.40% | +0.98% |
| YTD return | -41.28% | -28.77% |
| 1-year return | -54.85% | -13.11% |
| 5-year return | — | -84.91% |
| Forward P/E | — | 2.44 |
| EPS (TTM) | $-0.86 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $8.74 |
| 52-week low | $2.29 | $3.93 |
| Distance from 52-week high | -70.01% | -52.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +635.55% | +591.00% |
| Average volume | 276.60K | 834.69K |
| Shares outstanding | 45.25M | 27.39M |
| Employees | 25 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed GNLX by 41.7 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
GNLX vs UNCY FAQ
Which is bigger, Genelux or Unicycive Therapeutics?
Genelux (GNLX) is larger, with a market capitalization of $115.83M compared with $112.59M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, GNLX or UNCY?
UNCY returned -13.11% over the past 12 months, compared with -54.85% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.